☆ 4.7 Article

Effi cacy of a Small-Molecule Inhibitor of Kras G12D in Immunocompetent Models of Pancreatic Cancer

CANCER DISCOVERY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Medicine, General & Internal

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

Rom Leidner et al.

Summary: The patient with progressive metastatic pancreatic cancer showed regression of visceral metastases after receiving infusion of genetically engineered autologous T cells targeting mutant KRAS G12D, with an overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1. The response was ongoing at 6 months, and the engineered T cells accounted for more than 2% of all circulating peripheral-blood T cells.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin et al.

Summary: This study evaluated the mechanism and anti-tumor efficacy of MRTX1133, a non-covalent KRAS(G12D) inhibitor. Results showed that MRTX1133 had a high-affinity interaction with KRAS(G12D) and inhibited its activation, leading to tumor regression. Co-targeting additional pathways enhanced the anti-tumor activity.

NATURE MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming

Ashley Velez-Delgado et al.

Summary: This study reveals that non-cell autonomous oncogenic KRAS signaling can reprogram pancreatic fibroblasts, leading to an inflammatory response and affecting the tumor microenvironment, thereby promoting tumor development.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Review Oncology

Translational advances in pancreatic ductal adenocarcinoma therapy

Abdel Nasser Hosein et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages, leading to limited treatment options. Recent advancements in targeted therapy and immunotherapy for different subtypes of PDAC are reviewed in this article, with a focus on the current preclinical and clinical evidence supporting these approaches and the potential of combination treatments.

NATURE CANCER (2022)

Add to Collection

Article Medicine, Research & Experimental

The vascular landscape of human cancer

Benjamin M. Kahn et al.

Summary: Through studying the tumor vascular environment, the use of the endothelial index (EI) and vascular microenvironment signatures (VMS) can better assess tumor vascular density, which is associated with prognosis in certain cancer types. These findings suggest that these metrics may enable more precise deployment of antiangiogenesis therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Chemistry, Medicinal

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

Xiaolun Wang et al.

Summary: KRAS(G12D), the most common oncogenic KRAS mutation, is a promising target for solid tumor treatment. Selective inhibition of KRAS(G12C) presents a significant challenge due to the requirement of high affinity inhibitors to bind the mutant protein. The discovery of the noncovalent, potent, and selective KRAS(G12C) inhibitor MRTX1133, shown to be efficacious in a mouse tumor model, represents a significant advancement in the field.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Oncology

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere et al.

Summary: KRAS inhibition can reverse an immunosuppressive tumor microenvironment and sensitize tumors to checkpoint inhibitor therapy (CIT) through multiple mechanisms.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Adham S. Bear et al.

Summary: Activating RAS missense mutations are common in human cancers and can be immunologically targeted. By characterizing HLA class I-restricted mKRAS epitopes, the study successfully isolated and transferred mKRAS-specific TCR to CD8(+) T cells, demonstrating cytotoxicity against mKRAS tumor cells from various origins, with lytic activity correlating with peptide-HLA class I complex abundance. Adoptive transfer of mKRAS-TCR engineered CD8(+) T cells led to tumor eradication in a xenograft model, validating mKRAS peptides as epitopes for immune therapies.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Chemistry, Medicinal

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Multidisciplinary Sciences

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

Robert Vander Velde et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

RAS-targeted therapies: is the undruggable drugged?

Amanda R. Moore et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

Nune Markosyan et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Add to Collection

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

Add to Collection

Article Oncology

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma

Giulia Biffi et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Medicine, Research & Experimental

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Andrew M. Waters et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

Add to Collection

Article Oncology

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer

Andrew J. Rech et al.

CANCER RESEARCH (2018)

Add to Collection

Article Immunology

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Jinyang Li et al.

IMMUNITY (2018)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Immunology

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

Daniel Ohlund et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection

Article Biology

Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice

Yaqing Zhang et al.

ELIFE (2017)

Add to Collection

Article Oncology

The Pancreatic Cancer Microenvironment

Stephanie K. Dougan

CANCER JOURNAL (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

Add to Collection

Article Multidisciplinary Sciences

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey et al.

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

Metastatic progression is associated with dynamic changes in the local microenvironment

Nicole M. Aiello et al.

NATURE COMMUNICATIONS (2016)

Add to Collection

Article Oncology

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

Albert Lo et al.

CANCER RESEARCH (2015)

Add to Collection

Article Immunology

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

Rafael Carretero et al.

NATURE IMMUNOLOGY (2015)

Add to Collection

Article Oncology

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

Rafael Winograd et al.

CANCER IMMUNOLOGY RESEARCH (2015)

Add to Collection

Article Oncology

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Berna C. Oezdemir et al.

CANCER CELL (2014)

Add to Collection

Article Oncology

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Andrew D. Rhim et al.

CANCER CELL (2014)

Add to Collection

Article Oncology

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

Dominic E. Sanford et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Oncology

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

Paolo P. Provenzano et al.

CANCER CELL (2012)

Add to Collection

Article Oncology

Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer

Lauren J. Bayne et al.

CANCER CELL (2012)

Add to Collection

Article Biochemistry & Molecular Biology

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

Haoqiang Ying et al.

CELL (2012)

Add to Collection

Article Biochemistry & Molecular Biology

EMT and Dissemination Precede Pancreatic Tumor Formation

Andrew D. Rhim et al.

CELL (2012)

Add to Collection

Article Medicine, Research & Experimental

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

Meredith A. Collins et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection

Article Medicine, General & Internal

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Multidisciplinary Sciences

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice

Meredith A. Collins et al.

PLOS ONE (2012)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Multidisciplinary Sciences

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Gregory L. Beatty et al.

SCIENCE (2011)

Add to Collection

Article Oncology

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Richard E. Royal et al.

JOURNAL OF IMMUNOTHERAPY (2010)

Add to Collection

Article Multidisciplinary Sciences

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

Kenneth P. Olive et al.

SCIENCE (2009)

Add to Collection

Article Oncology

Trp53R172H and KraSG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

SR Hingorani et al.

CANCER CELL (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.